Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Cancer

Categories

[Search within category]

Small Molecule Regulators of let-7 MicroRNA Targets in Acute Myeloid Leukemia Cancer Stem Cells

UCLA researchers have identified a class of small molecule phosphodiesterase inhibitors that suppress let-7 target genes and inhibit cell growth in acute myeloid leukemia cancer cell lines.

Mucoadhesive Devices for Oral Delivery of Various Active Agents

Effective and easily accepted system of oral delivery of therapeutic drugs.

A Novel Air/Water Retention Device for Improved Visibility in Colonoscopies

Colon cancer is the third most common cancer diagnosed in men and women in the United States. It is also the third leading cause of cancer-related death in women and the second leading cause in men. Fortunately, over the last 20 years the death rate for this cancer has been decreasing. There are two primary reasons for this decrease, improvements in therapy and the increase in screening for and removal of colorectal polyps. A colonoscopy is recommended for adults over the age of fifty in the US. It is an examination of the colon performed by a gastroenterologist whereby an endoscope is inserted through the anus and into the colon. Most endoscopes have a camera and a light for visualization of the colon. In order to clearly see within the colon, which is in a naturally collapsed state, air or water is used to inflate the organ. Normally, a tight seal is formed around the scope to retain pressure inside the colon. But in some patients, a tight seal is not possible and is not able to retain the pressure making the procedure difficult to perform. Currently, the standard practice in these occasions is for a technician to use a towel to hold the anus shut.

High Frequency Digital Frequency Domain Fluorescence Lifetime Imaging System For Applications On Tissues

The technology is a software/hardware combination designed to enhance sampling rate for frequency domain fluorescence lifetime imaging. Fluorescence lifetime imaging microscopy (FLIM) is a technique that uses signals emitted from fluorescent samples to construct images of those samples in near real time. An advantage to FLIM is its ability to image large fields of view, which makes it an attractive option for dynamical measurements of live biological tissues. The higher sampling rate available using this technology will allow for more information to be gleaned from biological samples, which may have a fluorescence band up to 1 GHz, advancing tissue imaging.

Mobile Phone Based Fluorescence Multi-Well Plate Reader

UCLA researchers have developed a novel mobile phone-based fluorescence multi-well plate reader.

A New Therapeutic Approach To Create And Exploit Metabolic Vulnerabilities In Malignant Glioma And Other Cancers

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a novel cancer therapeutic approach that targets both metabolism and cell death signaling pathways, creating a synergistic killing effect that vastly increases treatment efficacy.

Lipoplex-Mediated Efficient Single-Cell Transfection Via Droplet Microfluidics

The invention is an on-chip, droplet based single-cell transfection platform providing higher efficiency and consistency compared to conventional methods. Novel techniques following cell encapsulation yields uniform lipoplex formation, which increases the transfection accuracy. The invention solves the dilemma of the trade-off between efficiency and cell viability, and offers a safe, cell friendly and high transfection solution that is crucial for applications like gene therapy, cancer treatment and regenerative medicine.

Novel Methodology To Convert Magnetic Resonance Imaging Scan Data To Be Used In Proton Beam Therapy

This invention is a novel model that uses magnetic resonance imaging (MRI) information to more accurately determine the irradiation area using proton beam therapy (PBT) for oncological treatment.

Generation of an Improved Synthetic Splice Modulator (FDGLY) That Mirrors the Structural Features of the Potential CLL In Vitro Inhibitor FD-895

 An increasing body of research has shown that alternations in RNA splicing are involved in a number of human diseases, particularly cancer. Drug regulation of splicing has become an interesting new target for therapeutic discovery. A number of drug discovery efforts aimed at developing splicing-modulating small-molecules are being tested in clinic trials for cancer.

Structurally Validated Anti-avß8 Antibodies for Targeting TGFß for Immunotherapy

This invention provides highly efficient antibodies whose epitopes and mechanism of action have been structurally defined against integrin αvβ8. These antibodies have been designed to be used as therapeutic for cancer. Other antibodies have been designed as companion diagnostic tools.

Novel Covalent Inhibitors Of GTP And GDP-bound RAS

This invention describes a novel class of direct Ras inhibitors that bind and inhibit this oncogene in its GTP and GDP-bound states.

A New Class of mTOR Inhibitors for Targeted Treatment of Anti-cancer, Anti-aging, and Anti-autism and Regenerative Medicine

Novel hybrid inhibitors of mTOR (mammalian target of rapamycin kinase) that selectively target mTORC1 (mammalian target of rapamycin complex 1) and completely inhibit downstream phosphorylation of its substrates for cancer treatment as well as regenerative medicine, aging and autism (TSC mutations).

A Novel CRISPR-based Screen for Personalized Cancer Therapy

Disease phenotypes are often regulated by interwoven genetic networks. For example, tumor genomes exhibit an extensive variety of genetic and epigenetic changes involved in tumor initiation, metastasis and ultimately, resistance to therapy. Combination therapy to target multiple pathways, as opposed to only single ones, can enhance treatment efficacy. Discovering effective combination therapies for human diseases is challenging with existing methods, due to the cost, effort, and labor required to construct and analyze each combination. There is a need for technological advances to accelerate the identification of effective combinatorial therapies. CRISPR has emerged as a new tool to systemically interrogate cancer genomes and set up the potential for personalized medicine. Personalized medicine is based upon the concept that individual differences can be identified and used to the patient’s advantage for therapy.

mTORC2 Specific Inhibitors

UCLA researchers have identified and characterized mTORC2-specific inhibitors useful as a novel treatment of glioblastoma.

Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.

Small Molecule Treatment for Androgen Inhibitor-Resistant Cancers

Researchers at the University of California, Davis have developed small molecule inhibitors of androgen receptor variants for the treatment of androgen inhibitor-resistant cancers.

Handled Blood-Flow Imaging Device

The invention is a medical handheld device that carries out skin visual inspection simultaneously with blood flow measurements through integrating a Laser Speckle Imaging (LSI) system within a handheld compact dermoscope. Combining both features in one compact, cheap and easy to use device will generate accurate and elaborative functional data that will improve the accuracy and detection of diseases such as cancer.

Small Molecules for Melanoma Treatment

Traditional anti-cancer treatments used for metastatic melanoma (skin cancer) can result in cell toxicity, poor efficacy, and low patient survival. UCI researchers have uncovered a class of potent compounds that inhibit cancer cell growth and induce cancer cell death by targeting RhoJ signaling pathways.

Bispecific Antibodies for Detection and Treatment of Cancers Associated with EGFR Overexpression

This invention identifies novel bispecific antibodies that can be used to detect and/or treat various cancers that overexpress EGFR family of proteins.

Polyketide Synthase Variants And Uses Thereof

Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of polyketides. These enzymes make attractive targets because they can be modified to produce commodity chemicals. The invention herein describes methods for producing polyketide synthase variants whose activity and/or substrate specificity can be tailored. An example of a polyketide synthase variant would be 2-pyrone synthase, which produces 2-pyrone. Other modified synthase variants can be generated to produce other key materials including ketides, lactones, etc.

Novel Anti-Bacterial, Anti-Fungal Nanopillared Surface

Medical devices are susceptible to contamination by harmful microbes, such as bacteria and fungi, which form biofilms on device surfaces. These biofilms are often resistant to antibiotics and other current treatments, resulting in over 2 million people per year suffering from diseases related to these contaminating microbes. Death rates for many of these diseases are high, often exceeding 50%. Researchers at UCI have developed a novel anti-bacterial and anti-fungal biocomposite that incorporates a nanopillared surface structure that can be applied as a coating to medical devices.

A Prognostic And Diagnostic Algorithm For Various Molecular Subtypes Of Breast Cancers, Including Her2 Positive And Triple Negative Breast Cancers (TNBCs)

Breast cancer is second leading cause of death among women in the United States in 2016 and It is estimated to be responsible for over 40,000 deaths in 2017 (ACS). The use of biomarkers plays a key role in the management of patients with breast cancer, especially in the decision process to select the appropriate systemic therapy to be administered. Furthermore, the discovery of new tissue-based and gene biomarkers has led to the development of a “molecular signature” for predicting patient outcome and treatment modalities. There are three subtypes of breast cancer that are determined by performing specific tests on a sample of the tumor. The first subtype is a tumor that is positive/negative for a hormone receptor, either estrogen (ER) and/or progesterone (PR); tumors without these receptors are classified “hormone receptor-negative”. The second subtype is characterized by the overexpression the human epidermal growth factor receptor 2 (HER2) protein on the tumor.  HER2 proteins are receptors on normal breast cells and help control the growth, but when overexpressed make the tumor grow faster and are designated HER2-positive tumors. The last subtype is designated triple-negative, since it does not express ER, PR, and/or HER2. 

Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs

Researchers at the University of California, Davis have developed an efficient method to chemically synthesize the endogenous lipid mediator, 22-hydroxydocosahexaenoic acid (22-HDoHE) which can be applied to related natural mediators and analogs.

Genetic Mechanisms Of Resistance To Anti-Pd-1/L1

UCLA researchers have identified a rare genetic mutation in the interferon receptor signaling pathway that can be used as a diagnostic to predict whether a patient will be or has become resistant to a cancer immunotherapy.

Rapid Screening and Identification of Antigenic Components in Tissues and Organs

Researchers at the University of California, Davis have developed an approach to rapidly screen and identify antigenic components in tissues and organs.

  • Go to Page: